drugset / Trial / NCT01814670

Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

NCT01814670 ↗

Phase 4 Completed 185 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.

Timeline

Start
2013-03-06
Primary completion
2014-07-31
Completion
2014-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 20 unknown Other

Indications

No indication recorded.